



**ENAM Securities**  
India Research

CMP: Rs 760  
Target Price: Rs 1,027  
Potential Upside: 35%  
Absolute Rating: **BUY**

# Cadila Healthcare

Relative to sector: **Outperformer**


## Milind Bhangale

Sr VP – Life Sciences  
Email: milind.bhangale@enam.com  
Tel: 9122 6754 7615

## Deepak Khetan

AVP – Life Sciences  
Email: deepak.khetan@enam.com

## Relative Performance



Source: Bloomberg, ENAM Research

## Stock data

No. of shares : 205 mn  
Market cap : Rs 155.6 bn  
52 week high/low : Rs 984 / Rs 703  
Avg. daily vol. (6mth) : 114,600 shares  
Bloomberg code : CDH IB  
Reuters code : CADI.BO

## Shareholding (%) Sep-11 QoQ chg

Category	Sep-11 (%)	QoQ chg
Promoters	74.8	0.0
FIs	6.0	0.3
MFs / UTI	6.1	(1.1)
Banks / FIs	5.5	0.1
Others	7.5	0.7

## Financial summary

Y/E Mar	Sales (Rs mn)	Adj.PAT (Rs mn)	Consensus EPS* (Rs.)	EPS (Rs.)	Change YoY (%)	P/E (x)	RoE (%)	RoCE (%)	EV/EBITDA (x)	DPS (Rs.)
2010	36,868	5,083	-	24.8	51.4	-	34.7	26.1	-	5.0
2011	46,302	7,500	-	36.6	47.4	-	38.4	31.6	-	7.0
2012E	52,977	8,062	40.0	39.4	7.5	19.3	34.0	32.6	13.9	8.0
2013E	59,121	9,557	48.9	46.7	18.6	16.3	33.0	35.2	11.8	8.0

Source: \* Consensus broker estimates, Company, ENAM estimates

## DOMESTIC SLOWDOWN IMPAIRS GROWTH

Cadila Healthcare (CDH) reported Q2FY12 sales of Rs 12.4 bn (up 11% YoY) and adj. PAT of Rs 1.8 bn (up 3% YoY) – below our estimates, on the back of continued pressure in the domestic formulations business.

### Key highlights (Other highlights overleaf)

- **Sales:** Grew 11% YoY to Rs 12.4 bn. Exports rose 15% YoY to Rs 5.5 bn driven by 24% YoY growth in formulations – largely led by 36% growth in the US (of which 26% was organic). Europe grew 5% to Rs 619 mn (down 19% QoQ), which as per the mgmt, was due to sluggishness in the overall mkt. Emerging markets declined 10% YoY owing to political unrest in MENA (esp. Sudan and Algeria). Domestic formulations rose by only 7% YoY to Rs 4.7 bn due to slowdown in overall mkt for acute therapies & inventory correction in few products. Consumer business grew 11% YoY to Rs 1.3 bn (witnessing competition from MNCs & slower mkt growth). JV sales were flat at Rs 750 mn as Hopira grew significantly (led by Docetaxel supply) while Nycomed registered a decline.
- **EBITDA:** Margin was flat at 22.3% vs. 22.6% in Q2FY11.
- **PAT:** Was up by only 3% YoY to Rs 1.8 bn as higher interest cost (up 42% YoY to Rs 255 mn) and depreciation (up 23% YoY to Rs 375 mn) partially offset the 9% rise in EBITDA.

### Reduce estimates and TP; Maintain BUY (35% upside CMP)

With multiple growth drivers in place and its constant focus on moving up the value chain, we believe CDH has entered the league of top Indian pharma cos. However, given the pressure on domestic growth in the short to medium term, we reduce our FY12E and FY13E EPS by 6% and 9% to Rs 39 and Rs 47 resp. Accordingly, we cut our TP to Rs 1,027 (22x FY13E EPS). **Maintain BUY.**

## Results update

(Rs mn)	Quarter ended					12 months ended		
	Sep-11	Sep-10	% Chg	Jun-11	% Chg	Mar-12E	Mar-11	% Chg
<b>Total Income</b>	<b>12,364</b>	<b>11,167</b>	<b>10.7</b>	<b>12,365</b>	<b>(0.0)</b>	<b>52,977</b>	<b>46,302</b>	<b>14.4</b>
<b>EBITDA</b>	<b>2,757</b>	<b>2,529</b>	<b>9.0</b>	<b>2,932</b>	<b>(6.0)</b>	<b>11,847</b>	<b>10,772</b>	<b>10.0</b>
Other income	110	39	-	63	75.0	262	131	99.8
<b>PBIDT</b>	<b>2,867</b>	<b>2,568</b>	<b>11.7</b>	<b>2,995</b>	<b>(4.3)</b>	<b>12,109</b>	<b>10,903</b>	<b>11.1</b>
Depreciation	375	304	23.3	347	8.1	1,600	1,269	26.1
Interest	255	179	42.1	189	35.1	800	699	14.4
<b>PBT</b>	<b>2,237</b>	<b>2,084</b>	<b>7.3</b>	<b>2,459</b>	<b>(9.0)</b>	<b>9,709</b>	<b>8,934</b>	<b>8.7</b>
Tax	352	262	34.4	235	50.0	1,323	1,184	11.7
Adjustment	75	60	25.5	45	68.2	325	251	29.3
<b>Adjusted PAT</b>	<b>1,810</b>	<b>1,762</b>	<b>2.7</b>	<b>2,180</b>	<b>(17.0)</b>	<b>8,062</b>	<b>7,500</b>	<b>7.5</b>
Extra ordinary (income)/ exp.	783	54	-	(118)	-	665	390	70.4
<b>Reported PAT</b>	<b>1,027</b>	<b>1,708</b>	<b>(39.9)</b>	<b>2,298</b>	<b>(55.3)</b>	<b>7,397</b>	<b>7,110</b>	<b>4.0</b>
No. of shares (mn)	205	205	0.0	205	0.0	205	205	0.0
EBITDA margin (%)	22.3	22.6	(35.3)	23.7	(6.0)	22.4	23.3	(3.9)
PBIDT margin (%)	23.2	23.0	0.8	24.2	(4.3)	22.9	23.5	(2.9)
<b>EPS - annualized (Rs.)</b>	<b>35.3</b>	<b>34.4</b>	<b>2.7</b>	<b>42.5</b>	<b>(17.0)</b>	<b>39.4</b>	<b>36.6</b>	<b>7.5</b>

Source: Company, ENAM Research

## Gross sales break-up

(Rs mn)	Sep-11	Sep-10	% Chg	Jun-11	% Chg
<b>Domestic (a)</b>					
- Formulations	4,700	4,409	6.6	4,574	2.8
- API	68	64	6.3	66	3.0
- Consumer & others	1,332	1,202	10.8	1,306	2.0
<b>Sub - Total</b>	<b>6,100</b>	<b>5,675</b>	<b>7.5</b>	<b>5,946</b>	<b>2.6</b>
<b>Exports (b)</b>					
- Formulations & others	4,977	4,002	24.4	4,136	20.3
- API	563	801	(29.8)	680	(17.3)
<b>Sub - Total</b>	<b>5,539</b>	<b>4,803</b>	<b>15.3</b>	<b>4,816</b>	<b>15.0</b>
<b>JVs (c)</b>	<b>750</b>	<b>735</b>	<b>2.0</b>	<b>1,127</b>	<b>(33.5)</b>
<b>Total sales (a+b+c)</b>	<b>12,389</b>	<b>11,213</b>	<b>10.5</b>	<b>11,889</b>	<b>4.2</b>

Source: Company

## Overseas formulation sales break-up

(Rs mn)	Sep-11	Sep-10	% Chg	Jun-11	% Chg
<b>Export Formulations &amp; others</b>	<b>4,977</b>	<b>4,002</b>	<b>24.4</b>	<b>4,136</b>	<b>20.3</b>
- US	3,070	2,258	36.0	2,393	28.3
- Europe	619	588	5.4	769	(19.5)
- Japan	120	98	21.8	112	7.0
- LATAM	655	584	12.2	470	39.4
- EM	429	474	(9.6)	392	9.4
- Bremer	84	0	-	0	-

Source: Company

### Other highlights

- ❑ **Domestic formulations to grow in lower double digits** – CDH is facing a slowdown in the domestic formulations growth (8% YoY growth in 1HFY12) due to: (a) overall sluggishness in acute therapies, and (b) inventory correction in few products in order to check receivables. The mgmt indicated that CDH would be launching 40 products in Q3FY12 and has undertaken a sales force effectiveness exercise. Consequently, mgmt expects 2HFY12 to be better.
- ❑ **US biz. to show 20% organic growth** – The mgmt has guided that US biz. would show 20% organic growth in FY12 led by focus on existing products and couple of new launches (launched three products in 1HFY12; expects to launch two more in 2HFY12).
- ❑ **Nesher acquisition** – Nesher contributed ~Rs 225 mn in Q2FY12. Also, the mgmt highlighted that the company is not EBITDA negative. CDH expects to launch two products in FY13 and three more in FY14.
- ❑ **Zydu Wellness** – Sugar Free franchise grew by only 6-7% during the quarter, as the market growth slowed down. On the positive side, the mgmt highlighted that CDH has been able to gain market share in this segment. Everyuth franchise's growth has been impacted by stiff competition from MNCs. EBITDA margin has been impacted as the production has been shifted to CDH's own manufacturing plant (vs. outsourcing earlier). However, with pick-up in capacity utilization, mgmt expects margins would plough back.
- ❑ CDH recorded a **forex loss** of Rs 900 mn in Q2FY12 (vs. Rs 62 mn in Q2FY11), of which Rs 386 mn was on account of forward contracts and Rs 514 mn was on account of long-term borrowings. Of the total, only Rs 68 mn of loss was realized.
- ❑ Management indicated that **R&D expenses** would be maintained at 5-6% of sales (6.6% in 1HFY12 and 4.9% in FY11).
- ❑ **Gross debt and cash** on books are at Rs 19.9 bn and Rs 6.1 bn resp. The mgmt highlighted that it is maintaining higher cash on books in order to meet expected acquisition.
- ❑ **Capex** – Guided for capex of Rs 5 bn for FY12E. Bulk of this, would be on Greenfield projects (on bio-similars and monoclonal vaccines), which are expected to be commissioned by FY13. This also includes Nesher acquisition.
- ❑ **Tax rate** – The company reiterated that tax rate for FY12E would be at ~15%.

---

This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Nothing in this document should be construed as investment or financial advice, and nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. The intent of this document is not in recommendatory nature

Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors

Enam Securities Private Limited has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval

Enam securities Private Limited, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document

This report has been prepared on the basis of information, which is already available in publicly accessible media or developed through analysis of ENAM Securities Private Limited. The views expressed are those of analyst and the Company may or may not subscribe to all the views expressed therein

This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions

Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

**Copyright in this document vests exclusively with ENAM Securities Private Limited.**